タイトル | Uncompetitive, adduct-forming SARM1 inhibitors are neuroprotective in preclinical models of nerve injury and disease. |
---|
ジャーナル・号・ページ | Neuron, Vol. 110, Page 3711-, Year 2022 |
---|
掲載日 | 2022年5月26日 (構造データの登録日) |
---|
著者 | Bratkowski, M. / Burdett, T.C. / Danao, J. / Wang, X. / Mathur, P. / Gu, W. / Beckstead, J.A. / Talreja, S. / Yang, Y.S. / Danko, G. ...Bratkowski, M. / Burdett, T.C. / Danao, J. / Wang, X. / Mathur, P. / Gu, W. / Beckstead, J.A. / Talreja, S. / Yang, Y.S. / Danko, G. / Park, J.H. / Walton, M. / Brown, S.P. / Tegley, C.M. / Joseph, P.R.B. / Reynolds, C.H. / Sambashivan, S. |
---|
リンク | Neuron / PubMed:36087583 |
---|
手法 | X線回折 |
---|
解像度 | 1.74 - 2.37 Å |
---|
構造データ | PDB-8d0c: Human SARM1 TIR domain bound to NB-3-ADPR 手法: X-RAY DIFFRACTION / 解像度: 2.09 Å PDB-8d0d: Human SARM1 TIR domain bound to an NB-7-ADPR adduct 手法: X-RAY DIFFRACTION / 解像度: 1.96 Å PDB-8d0e: Human SARM1 TIR domain bound to NB-7 手法: X-RAY DIFFRACTION / 解像度: 1.88 Å PDB-8d0f: Human SARM1 TIR domain bound to NB-2-ADPR 手法: X-RAY DIFFRACTION / 解像度: 1.74 Å PDB-8d0g: Human SARM1 TIR domain bound to NB-3-ADPRP 手法: X-RAY DIFFRACTION / 解像度: 1.99 Å PDB-8d0h: Human SARM1 TIR domain bound to NB-3-GDPR 手法: X-RAY DIFFRACTION / 解像度: 2.37 Å PDB-8d0i: Human SARM1 bound to an NB-3 eADPR adduct 手法: X-RAY DIFFRACTION / 解像度: 2 Å PDB-8d0j: Apo Human SARM1 TIR domain 手法: X-RAY DIFFRACTION / 解像度: 1.94 Å PDB-8d0m: Human CD38 ectodomain bound to a 78c-ADPR adduct 手法: X-RAY DIFFRACTION / 解像度: 2.04 Å |
---|
化合物 | ChemComp-Q1F: [[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(2~{R},3~{S},4~{R},5~{R})-5-[4-[(1~{S})-1-[methyl-[2,2,2-tris(fluoranyl)ethylcarbamoyl]amino]ethyl]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methyl hydrogen phosphate
ChemComp-Q0L: [[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(2~{R},3~{S},4~{R})-5-[4-[3-[3-(4-chlorophenyl)propanoylamino]-4-methyl-1~{H}-pyrazol-5-yl]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methyl hydrogen phosphate
ChemComp-Q0C: 3-(4-chlorophenyl)-N-[4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl]propanamide
ChemComp-Q0U: [[(3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(2~{R},3~{S},4~{R},5~{R})-5-[4-[[methyl-[2,2,2-tris(fluoranyl)ethylcarbamoyl]amino]methyl]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methyl hydrogen phosphate
ChemComp-Q1X: [[(2~{R},3~{R},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3-oxidanyl-4-phosphonooxy-oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(2~{R},3~{S},4~{R},5~{R})-5-[4-[(1~{S})-1-[methyl-[2,2,2-tris(fluoranyl)ethylcarbamoyl]amino]ethyl]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methyl hydrogen phosphate
ChemComp-Q1O: [[(2~{R},3~{S},4~{R},5~{R})-5-(2-azanyl-6-oxidanylidene-3~{H}-purin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(2~{R},3~{S},4~{R},5~{R})-5-[4-[(1~{S})-1-[methyl-[2,2,2-tris(fluoranyl)ethylcarbamoyl]amino]ethyl]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methyl hydrogen phosphate
ChemComp-PZ7: [[(2~{R},3~{S},4~{R},5~{R})-5-imidazo[2,1-f]purin-3-yl-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(2~{R},3~{S},4~{R},5~{R})-5-[4-[(1~{S})-1-[methyl-[2,2,2-tris(fluoranyl)ethylcarbamoyl]amino]ethyl]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methyl hydrogen phosphate
ChemComp-Q2C: [[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(2~{R},3~{S},4~{R},5~{R})-5-[5-[4-[[4-(2-methoxyethoxy)cyclohexyl]amino]-1-methyl-2-oxidanylidene-quinolin-6-yl]-1,3-thiazol-3-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methyl hydrogen phosphate
|
---|
由来 | - homo sapiens (ヒト)
|
---|
キーワード | HYDROLASE/INHIBITOR / NAD / hydrolase / axon degeneration / neuroscience / HYDROLASE-INHIBITOR complex |
---|